In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Valeant goes hostile and offers $73/share for Cephalon; withdrawn
02 May 2011
Taking its offer directly to investors, Valeant Pharmaceuticals International Inc. (focuses on skin and CNS drugs) has publicly announced a $73 per-share cash bid (a 30% premium) for Cephalon Inc., valuing the top-tier biotech at $5.5bn, or almost twice its 2010 sales. Valeant plans to finance the transaction using debt, and wants to replace Cephalon’s board with its own nominees. Beginning earlier this month, Valeant privately approached Cephalon three times, but Valeant says the target did not want to enter into further discussions in a timely manner, and that Cephalon’s CEO believed the board would consider the offer too low.
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?